Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma

K.A. Frerichs, M.C. Minnema, M.D. Levin, A. Broijl, G.M.J. Bos, M.J. Kersten, T. Mutis, C.P.M. Verkleij, I.S. Nijhof, P.W.C. Maas-Bosman, S.K. Klein, S. Zweegman, P. Sonneveld, N.W.C.J. van de Donk*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Web of Science)
Original languageEnglish
Pages (from-to)5128-5139
Number of pages12
JournalBlood advances
Volume5
Issue number23
DOIs
Publication statusPublished - 14 Dec 2021

Keywords

  • CD38 EXPRESSION
  • OPEN-LABEL
  • INTRAVENOUS DARATUMUMAB
  • UP-REGULATION
  • CELLS
  • DEXAMETHASONE
  • LENALIDOMIDE
  • MONOTHERAPY
  • BORTEZOMIB
  • EXPANSION

Cite this